By a News Reporter-Staff News Editor at Drug Week -- Research findings on Cancer Prevention are discussed in a new report. According to news originating from Bethesda, Maryland, by NewsRx correspondents, research stated, "Head and neck squamous cell carcinoma (HNSCC) is a major public health concern. The recent identification of the mTOR complex 1 (mTORC1) signaling pathway as a highly prevalent molecular signature underlying HNSCC pathogenesis has provided the foundation to search for novel therapeutic approaches to prevent and treat HNSCC."
Our news journalists obtained a quote from the research from the National Institute of Dental and Craniofacial Research, "Here, we asked whether metformin, the most widely used medication for the treatment of type II diabetes, which acts in part by stimulating the AMP-activated protein kinase (AMPK) signaling pathway thereby reducing mTORC1 activity, may lower the risk of HNSCC development. Indeed, we show that metformin reduces the growth of HNSCC cells and diminishes their mTORC1 activity by both AMPK-dependent and -independent mechanisms. We also optimized an oral-specific carcinogenesis mouse model that results in the accumulation of multiple oral premalignant lesions at the end of the carcinogen exposure, some of which then spontaneously progress into HNSCC. Using this mouse model, we observed that metformin specifically inhibits mTORC1 in the basal proliferating epithelial layer of oral premalignant lesions. Remarkably, metformin prevented the development of HNSCC by reducing significantly the size and number of carcinogen-induced oral tumoral lesions and by preventing their spontaneous conversion to squamous cell carcinomas."
According to the news editors, the research concluded: "Collectively, our data underscore the potential clinical benefits of using metformin as a targeted chemopreventive agent in the control of HNSCC development and progression."
For more information on this research see: Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prevention Research, 2012;5(4):562-73. (American Association for Cancer Research - www.aacr.com; Cancer Prevention Research - cancerpreventionresearch.aacrjournals.org/)
The news correspondents report that additional information may be obtained from L. Vitale-Cross, Molecular Carcinogenesis Section, Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, United States (see also Cancer Prevention).
Keywords for this news article include: Antidiabetic Agents, Drugs, Therapy, Bethesda, Maryland, Oncology, Metformin, Biguanides, United States, Cancer Prevention, Non Sulfonylureas, Hypoglycemic Agents, North and Central America, Oral Squamous Cell Carcinoma.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .
Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.